Greenphire Launches GreenSpace App
Greenphire has unveiled a new patient-facing digital platform, GreenSpace.
GreenSpace offers a unified digital experience accessible via iOS and Android devices, or through an internet browser. The platform provides access to trial-related information and activities such as financial views and account details, submission of receipts for reimbursement, visit and travel itinerary details, delivery of surveys and insights, and more.
In addition to GreenSpace, Greenphire has also expanded its payment offerings available through ClinCard. The solution will offer a suite of payment modalities for both banked and unbanked study populations. This provides patients with the ability to choose from options that best align with their personal needs, including reloadable debit cards, virtual cards, digital wallets, email to money and bank transfers that are real-time, low cost to customers, and zero fees for patients.
Reference
Greenphire Launches GreenSpace App and Expands Global Payment Functionality. (2023, April 25). Cision PR Newsire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
